KDM6A and breast cancer: Kaplan-Meier analysis showed that BC patients with a high KDM6A mRNA (top 15%, n = 61) levels had significantly longer overall survival than those with low KDM6A levels (bottom 15%, n = 61) (Fig. 2B).